Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Non-Current Assets (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Non-Current Assets for 3 consecutive years, with $18.3 million as the latest value for Q4 2025.

  • For Q4 2025, Non-Current Assets fell 12.77% year-over-year to $18.3 million; the TTM value through Dec 2025 reached $79.2 million, down 46.28%, while the annual FY2025 figure was $18.3 million, 12.77% down from the prior year.
  • Non-Current Assets hit $18.3 million in Q4 2025 for Artiva Biotherapeutics, down from $19.3 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $75.0 million in Q3 2024 and bottomed at $18.3 million in Q4 2025.
  • Average Non-Current Assets over 3 years is $28.3 million, with a median of $21.1 million recorded in 2024.
  • On a YoY basis, Non-Current Assets climbed as much as 12.77% in 2025 and fell as far as 74.23% in 2025.
  • Artiva Biotherapeutics' Non-Current Assets stood at $25.3 million in 2023, then dropped by 17.17% to $21.0 million in 2024, then dropped by 12.77% to $18.3 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $18.3 million, $19.3 million, and $20.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.